The roller-coaster ride that is Aveo Oncology Inc. took another dip Friday when the Cambridge, Mass.-based company reported written feedback from the FDA on the development of a biomarker that would help predict the response of patients with colorectal cancer (CRC) to tivozanib (tivo) compared with Avastin (bevacizumab, Roche AG).